Ozempic for chronic kidney disease (ckd)
How Ozempic (semaglutide) is used in chronic kidney disease (ckd), what the clinical evidence shows, and how it compares to other treatment options.
Chronic kidney disease (CKD): what it is
Chronic kidney disease is progressive loss of kidney function over months to years. Classified by estimated glomerular filtration rate (eGFR) into 5 stages: G1 (normal eGFR ≥90 with structural damage) through G5 (eGFR <15, kidney failure). Diabetes and hypertension drive the majority of US CKD.
How Ozempic fits into chronic kidney disease (ckd) treatment
Aggressive blood pressure and glucose control. RAS blockade (ACE inhibitor or ARB) for albuminuria. SGLT2 inhibitors (dapagliflozin, empagliflozin) shown to slow CKD progression independent of diabetes status. Finerenone for CKD in T2D. Semaglutide (Ozempic) gained CKD indication in 2026 based on the FLOW trial. Renal replacement therapy (dialysis or transplant) for kidney failure.
Ozempic works by: Same mechanism as Wegovy — GLP-1 receptor agonist. Lowers blood glucose by improving insulin response to meals and slowing gastric emptying. Weight loss is a side effect of appetite suppression.
Who qualifies for Ozempic for chronic kidney disease (ckd)
FDA-approved indication: adults with type 2 diabetes for glycemic control and CV risk reduction. Many telehealth platforms prescribe off-label for weight management when Wegovy is unavailable or insurance won't cover Wegovy.
Clinical evidence
1.4–1.8% HbA1c reduction across SUSTAIN trials (1.0 mg dose)
Trial: SUSTAIN-6 (NCT01720446) — cardiovascular outcomes · vs placebo, 26% reduction in major adverse cardiovascular events · N = 3,297
How Ozempic compares to other chronic kidney disease (ckd) treatments
Ozempic is the only drug in our catalog currently used for chronic kidney disease (ckd). See the Chronic kidney disease (CKD) hub for additional treatment context.
Frequently asked about chronic kidney disease (ckd)
- Can chronic kidney disease be reversed?
- CKD is generally progressive but treatment slows or stops progression in most patients. Early-stage CKD (G1-G2 with mild albuminuria) can sometimes stabilize or improve with aggressive risk-factor management. Late-stage CKD (G4-G5) typically progresses to kidney failure without intervention.
- Is Ozempic actually approved for kidney disease?
- Yes. The FLOW trial showed semaglutide reduced the composite of major kidney events, kidney death, and cardiovascular death by 24% in patients with CKD and T2D. The FDA added a CKD indication to Ozempic's label in 2026. Same molecule as Wegovy but the CKD indication is on the Ozempic (T2D) label, not Wegovy (obesity).
- Why do my doctors check my eGFR every visit?
- eGFR is the headline measure of overall kidney function. Sustained decline of ≥30% indicates progression that warrants intervention. The trend matters more than any single value — annual monitoring at minimum, more frequent if you're on medications cleared by the kidneys or have diabetes/hypertension.
- Can I take metformin if I have CKD?
- Metformin is generally safe down to eGFR 30 mL/min/1.73m². Below that the lactic acidosis risk rises and metformin should be discontinued. Many patients with mild-moderate CKD continue metformin appropriately; this is a per-patient decision based on the specific eGFR and trend.